CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 30,000 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Samarth Kulkarni also recently made the following trade(s):
- On Monday, October 14th, Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04.
CRISPR Therapeutics Stock Performance
Shares of CRISPR Therapeutics stock opened at $49.79 on Thursday. CRISPR Therapeutics AG has a 52-week low of $43.42 and a 52-week high of $91.10. The stock has a market capitalization of $4.25 billion, a PE ratio of -17.59 and a beta of 1.67. The company has a 50-day simple moving average of $47.80 and a two-hundred day simple moving average of $52.12.
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
From Colonial Metals | Ad
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you.
A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Claim your FREE 2024 Gold Guide
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period last year, the business posted ($1.41) EPS. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -5.2 EPS for the current fiscal year.
Wall Street Analyst Weigh In
CRSP has been the subject of several research analyst reports. StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Thursday, November 7th. Royal Bank of Canada reiterated a "sector perform" rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Stifel Nicolaus dropped their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a "hold" rating for the company in a research report on Tuesday, August 6th. Finally, Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a "buy" rating on the stock in a research note on Tuesday, August 6th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $74.94.
Get Our Latest Analysis on CRISPR Therapeutics
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC lifted its stake in shares of CRISPR Therapeutics by 10.1% in the 1st quarter. ProShare Advisors LLC now owns 5,791 shares of the company's stock valued at $395,000 after purchasing an additional 530 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of CRISPR Therapeutics in the first quarter valued at $1,723,000. Blair William & Co. IL lifted its holdings in shares of CRISPR Therapeutics by 8.2% in the 1st quarter. Blair William & Co. IL now owns 147,890 shares of the company's stock worth $10,080,000 after acquiring an additional 11,190 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of CRISPR Therapeutics by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company's stock worth $111,564,000 after purchasing an additional 46,148 shares during the period. Finally, Orion Capital Management LLC boosted its position in shares of CRISPR Therapeutics by 44.0% during the first quarter. Orion Capital Management LLC now owns 720 shares of the company's stock valued at $49,000 after buying an additional 220 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.
CRISPR Therapeutics Company Profile
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
